Search form

Search form

The combination of danoprevir and Roche's experimental drug RG7128 appeared safe and well-tolerated in hepatitis C patients compared with placebo during an early-stage study. Those who received the highest doses of both drugs twice a day demonstrated a significant reduction in viral load after 13 days.

Related Summaries

FDA staff members will request an advisory panel's input regarding heart risk posed by Amgen's Aranesp and other anemia treatments to patients with chronic kidney disease. Advisers are scheduled next week to review clinical data from a study showing that Aranesp didn't significantly reduce death and cardiovascular events in kidney patients who were not on dialysis.

In a notice published in the journal Nature, three researchers at the Harvard Stem Cell Institute retracted a Jan. 28 article, which found that the aging process in older mice could be inhibited by rejuvenating blood stem cells. The retraction comes after Amy Wagers, the paper's lead author, found information that she said "undermined" her belief in the study. Shane Mayack, who also was involved in the study, didn't sign the retraction.

The combination of danoprevir and Roche's experimental drug RG7128 appeared safe and well-tolerated in hepatitis C patients compared with placebo during an early-stage study. Those who received the highest doses of both drugs twice a day demonstrated a significant reduction in viral load after 13 days.

A KLAS report, offered for free to providers, rates ambulatory EMR products used in 10 common physician specialties. The systems received ratings based on customer feedback and measures such as implementation quality.